Trial
NCT03066206
Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
M.D. Anderson Cancer Center
Collaborators
National Cancer Institute (NCI); Spectrum Pharmaceuticals, Inc
Condition
EGFR Exon 20 Mutation
Intervention
Poziotinib
Why stopped
\<75% participation
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-20